XML 25 R13.htm IDEA: XBRL DOCUMENT v3.25.3
Note 6 - Marketable Equity Securities
 9 Months Ended
Sep. 30, 2025
Notes to Financial Statements  
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

6.

Marketable Equity Securities

 

In April 2023, the Company received shares of common stock of Harvard Apparatus Regenerative Technology, Inc. (“HRGN”, formerly known as Biostage, Inc.) in connection with settlement of indemnification obligations related to litigation which was resolved during the year ended December 31, 2022.

 

During the nine months ended September 30, 2024, the Company sold all of its remaining HRGN shares. The Company received cash proceeds of $1.4 million and $1.9 million from HRGN shares sold during the three and nine months ended September 30, 2024, respectively. The Company recorded losses on equity securities of $0.3 million and $1.6 million during the three and nine months ended September 30, 2024, respectively. The Company determined the fair value of its HRGN common stock based on the closing price as quoted on the OTCQB Marketplace at the reporting date. The Company did not hold any shares of HRGN stock during the nine months ended September 30, 2025.